Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025
December 17, 2024 08:00 ET
|
Immuneering Corporation
Immuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025
Leapfrog Bio Presents Novel Genetic Sensitizing Mutation Linked to BET Inhibitors and Clinical Development Plans for Lead Product Candidate at the AACR Special Conference in Cancer Research
December 10, 2024 08:00 ET
|
Leapfrog Bio
Leapfrog Bio announced AACR presentation describing the discovery, characterization, and clinical development plan for lead drug LFB-190.
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
October 15, 2024 08:00 ET
|
Immuneering Corporation
Immuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic Cancer
Targeted Oncology™ announces Eric Cheung, D.O., as the second recipient of the 2024 Oncology Icons award
October 10, 2024 09:00 ET
|
Targeted Oncology™
CRANBURY, N.J., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Targeted Oncology™, a multimedia resource that offers engaging content and expert opinions on standard and emerging treatments in the field of...
Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 06, 2024 16:05 ET
|
Immuneering Corporation
Immuneering Reports Second Quarter 2024 Financial Results and Provides Business Updates
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer
July 31, 2024 16:05 ET
|
Immuneering Corporation
Immuneering Granted FDA Fast Track Designation for IMM-1-104 in First-line Pancreatic Cancer
Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
May 07, 2024 16:05 ET
|
Immuneering Corporation
Immuneering Reports First Quarter 2024 Financial Results and Provides Business Updates
Immuneering Recognizes Melanoma Awareness Month
May 06, 2024 16:30 ET
|
Immuneering Corporation
Immuneering Recognizes Melanoma Awareness Month
Targeted Oncology™ announces first recipient of 2024 for its Oncology Icons award program
April 23, 2024 10:46 ET
|
Targeted Oncology™
CRANBURY, N.J., April 23, 2024 (GLOBE NEWSWIRE) -- Targeted Oncology™, a multimedia resource that offers engaging content and expert opinions on standard and emerging treatments in the field of...
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
April 09, 2024 12:00 ET
|
Immuneering Corporation
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models